NJ-PMC-GROUP
23.2.2021 00:30:13 CET | Business Wire | Press release
PMC Group International, Inc., which is an independent arm of PMC Group Companies, announced the acquisition of Cobra Investments Management Inc. and its two subsidiaries, Copperhead Chemical Company Inc. (“Copperhead”) and Copperhead Investments Inc., from a group of previous owners of these entities, effective February 5, 2021. Copperhead is the manufacturing arm of the three acquired entities and is located on an 875 acres facility with 53 buildings in Tamaqua, Pennsylvania.
Copperhead has been the sole manufacturer of the FDA approved cardiac therapeutic drug nitroglycerin in the US for over 70 years and a custom manufacturer of drug dosage forms. It is also a major producer of energetic chemicals (explosives and propellants) for the defense industry as well as a novel class of preservatives and antimicrobials. Copperhead’s products are sold globally.
“The acquisition of Copperhead and its associated companies increases our penetration of the pharma market,” said Dr. Raj Chakrabarti, President of PMC Group International. According to Dr. Chakrabarti “this new acquisition will fit neatly and synergistically with our other Pharmaceutical services and manufacturing companies – especially PMC Isochem in France with three sites that include manufacturing of excipients and APIs as well as protein engineering, drug development and drug discovery services; and PMC YM-Pharma in Hyderabad, India, which provides process development and advanced pharmaceutical intermediate manufacturing services.” Dr. Raj Chakrabarti added that Copperhead will also have further manufacturing and marketing synergies with PMC Ouvrie, which is a leading supplier of defoamers, surfactants, and protective colloids for food and other industrial applications. He further added that “with the acquisition of Copperhead, PMC Group International is now poised to provide an end-to-end CDMO offering spanning all phases of drug development and manufacturing across three continents.”
ABOUT PMC Group Companies:
PMC Group is a US based growth oriented, diversified, global chemicals and pharmaceuticals company dedicated to innovative solutions to every need in a broad range of end markets including, plastics, consumer products, electronics, coatings, packaging, mining, personal care, food, automotive and pharmaceuticals. The Company was built on a sustainable model of growth through innovation while promoting social good. PMC operates from a global manufacturing, innovation, and marketing platform with facilities in the Americas, Europe, and Asia. More information about PMC Group and its activities around the world can be found at www.pmc-group.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005953/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference26.5.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with a fireside chat at 10:00 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com
GlobalPlatform Launches Pavona: The First Open Silicon Distribution with Production-Grade Post-Quantum Cryptography26.5.2026 12:00:00 CEST | Press release
Founding members — including Agile Analog, Analog Devices, Baochip, CrossBar, Max Planck Institute for Security and Privacy, Meta, University of Oxford, SIMPLE Crypto Association, Qualcomm Technologies, Tenstorrent, Winbond, and ZeroRISC — join community-led initiative to deliver certification-ready, composable silicon IP from datacenter to IoT. GlobalPlatform today launched Pavona, an open-source silicon distribution that delivers production-quality, certification-ready IP components and reference top-level designs — including the first openly available post-quantum cryptography (PQC) stack for embedded silicon. The distribution includes two successfully taped-out reference designs—a standalone chip root of trust and an integrated root of trust for chiplet architectures fabricated at TSMC 3nm (N3). Pavona provides a composable framework for building secure-by-default silicon aligned with FIPS 140-3 and Common Criteria certification requirements. Twelve founding members have already co
Croma Skincare – Where Science Meets Skin26.5.2026 11:43:00 CEST | Press release
With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines. Building on 50 years of experience in hyaluronic acid, Croma Pharma developed this skincare range to bridge the gap between in-clinic treatments and at-home care. The result is a streamlined portfolio that supports key skin needs such as hydration, glow, balance, and protection. The formulations combine high-performance actives including niacinamide, peptides, hyaluronic acid, and plant stem cells with lightweight, fast-absorbing textures that strengthen the skin barrier and enhance overall skin health. Hero products include: THE GLOW - a 20% stabilized vitamin C serum for radiance, antioxidant protection,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom